The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Polunina T.E.

Russian University of Medicine (A.I. Evdokimov Moscow State Medical University);
EMC Medical School

Sad consequences

Authors:

Polunina T.E.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2024;(1‑2): 28‑40

Read: 971 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Polunina TE. Sad consequences. Non Nocere. New Therapeutic Journal. 2024;(1‑2):28‑40. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Drug-induced liver lesions: classification, features of diagnosis and therapy

Authors:

Polunina T.E.

Russian University of Medicine (A.I. Evdokimov Moscow State Medical University);
EMC Medical School

Close metadata

References:

  1. Fontana RJ, Bjornsson ES, Reddy R, Andrade RJ. The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury. Clin Gastroenterol Hepatol. 2023;21(8):2088–2099. https://doi.org/10.1016/j.cgh.2022.12.040
  2. Maev I.V., Polunina T.E. Drug-induced liver injury: diagnosis of exclusion // Terapevticheskii arkhiv. – 2023. – Vol. 95. – N. 8. – P. 611-620.  https://doi.org/10.26442/00403660.2023.08.202329
  3. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1999.
  4. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354:731–739. 
  5. Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017 Jun;66(6):1154–1164. https://doi.org/10.1136/gutjnl-2016-313369
  6. Vasiliev A.P., Ivlev A.S., Rodin Yu.A., Polunina T.E., Kargina N.A. Clinical symptomatology of acute drug-induced hepatitis. Russian Journal of Gastroenterology, Hepatology. 1993;3:56-60. 
  7. Sandhu N, Navarro V. Drug-Induced Liver Injury in GI Practice. Hepatol Commun. 2020;4(5):631–645.  https://doi.org/10.1002/hep4.1503
  8. Swain MG, Jones DEJ. Fatigue in chronic liver disease: New insights and therapeutic approaches. Liver Int. 2019 Jan;39(1):6–19. Epub 2018 Aug 10  https://doi.org/10.1111/liv.13919
  9. Raikhelson K.L., Kondrashina E.A. Ademethionine in the treatment of fatigue in liver diseases: a systematic review // Terapevticheskii arkhiv. – 2019. – Vol. 91. – N. 2. – P. 134-142.  https://doi.org/10.26442/00403660.2019.02.000130
  10. Katarey D, Verma S. Drug-induced liver injury. Clin Med (Lond). 2016 Dec;16(Suppl 6):s104–s109. https://doi.org/10.7861/clinmedicine.16-6-s104
  11. Francis P, Navarro VJ. Drug-Induced Hepatotoxicity. 2022 Nov 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 
  12. Real M, Barnhill MS, Higley C, Rosenberg J, Lewis JH. Drug-Induced Liver Injury: Highlights of the Recent Literature. Drug Saf. 2019 Mar;42(3):365–387.  https://doi.org/10.1007/s40264-018-0743-2
  13. Ivanova D.A., Borisov S.E. Risk Assessment and Monitoring of Hepatotoxic Reactions in Tuberculosis Patients. Tuberculosis and Lung Diseases. 2017;95(9):40-48. (In Russ.) https://doi.org/10.21292/2075-1230-2017-95-9-40-48
  14. Polunina T.E., Maev I.V. Drug-induced hepatitis. Consilium medicum. Gastroenterology. 2008;1:3-9. 
  15. Sukhanov D.S., Romantsov M.G. Effects of hepatoprotector in liver damage in patients with respiratory tuberculosis. Advances in Current Natural Sciences. 2008;10:40-50. 
  16. Bezvulyak E.I., Basharin V.A., Epifantsev A.V., Kutsenko V.P., Seliverstov P.V. Prevention options of toxic drug-induced liver disease in patients with chemotherapy of oncological diseases. Meditsinskiy sovet = Medical Council. 2020;(5):42-49. (In Russ.) https://doi.org/10.21518/2079-701X-2020-5-42-49
  17. Ivashkin V.T., Baranovsky A.Yu., Raikhelson K.L., Palgova L.K., Maevskaya M.V., Kondrashina E.A., Marchenko N.V., Nekrasova T.P., Nikitin I.G. Drug-Induced Liver Injuries (Clinical Guidelines for Physicians). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):85-115. (In Russ.) https://doi.org/10.22416/1382-4376-2019-29-1-101-131
  18. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H, Gu J, Serrano J; United States Drug Induced Liver Injury Network. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology. 2015 Jun;148(7):1340–1352.e7.  https://doi.org/10.1053/j.gastro.2015.03.006
  19. Hoofnagle JH, Björnsson ES. Drug-Induced Liver Injury – Types and Phenotypes. N Engl J Med. 2019;381:264–273.  https://doi.org/10.1056/NEJMra1816149
  20. Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol. 2005;33(1):1–5.  https://doi.org/10.1080/01926230590888306
  21. Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010 Dec;52(6):2065–2076. https://doi.org/10.1002/hep.23937
  22. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, Schiødt FV, Ostapowicz G, Shakil AO, Lee WM; Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005 Dec;42(6):1364–1372. https://doi.org/10.1002/hep.20948
  23. Battipaglia G, Labopin M, Candoni A, Fanin R, El Cheikh J, Blaise D, Michallet M, Ruggeri A, Contentin N, Ribera JM, Stadler M, Sierra J, von dem Borne PA, Bloor A, Socié G, Nagler A, Mohty M. Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2017 Apr;52(4):592–599.  https://doi.org/10.1038/bmt.2016.302
  24. Suárez Ferrer C, Llop Herrera E, Calvo Moya M, Vera Mendoza MI, González Partida I, González Lama Y, Matallana Royo V, Calleja Panero JL, Abreu García L. Idiopathic portal hypertension regarding thiopurine treatment in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2016 Feb;108(2):79–83.  https://doi.org/10.17235/reed.2015.3954/2015
  25. Morris-Stiff G, White AD, Gomez D, Cameron IC, Farid S, Toogood GJ, Lodge JP, Prasad KR. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases. Eur J Surg Oncol. 2014 Aug;40(8):1016–1620. https://doi.org/10.1016/j.ejso.2013.09.015
  26. Dragovic G, Jevtovic D. The role of nucleoside reverse transcriptase inhibitors usage in the incidence of hyperlactatemia and lactic acidosis in HIV/AIDS patients. Biomed Pharmacother. 2012 Jun;66(4):308–311.  https://doi.org/10.1016/j.biopha.2011.09.016
  27. de Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, Kleiner DE, Hoofnagle JH; Drug-Induced Liver Injury Network. Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. Clin Gastroenterol Hepatol. 2017 Jan;15(1):103–112.e2.  https://doi.org/10.1016/j.cgh.2016.05.043
  28. Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R, Talwalkar JA, Stolz A, Gu J, Barnhart H, Hoofnagle JH; Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014 Feb;59(2):661–670.  https://doi.org/10.1002/hep.26709
  29. Devarbhavi H, Raj S, Aradya VH, Rangegowda VT, Veeranna GP, Singh R, Reddy V, Patil M. Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis: Patient characteristics, causes, and outcome in 36 cases. Hepatology. 2016 Mar;63(3):993–999.  https://doi.org/10.1002/hep.28270
  30. Knowles SR, Dewhurst N, Shear NH. Anticonvulsant hypersensitivity syndrome: an update. Expert Opin Drug Saf. 2012 Sep;11(5):767–778.  https://doi.org/10.1517/14740338.2012.705828
  31. Stolz A, Navarro V, Hayashi PH, Fontana RJ, Barnhart HX, Gu J, Chalasani NP, Vega MM, Bonkovsky HL, Seeff LB, Serrano J, Avula B, Khan IA, Cirulli ET, Kleiner DE, Hoofnagle JH; DILIN Investigators. Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. Aliment Pharmacol Ther. 2019 May;49(9):1195–1204. https://doi.org/10.1111/apt.15211
  32. Sacks FM, Stanesa M, Hegele RA. Severe hypertriglyceridemia with pancreatitis: thirteen years’ treatment with lomitapide. JAMA Intern Med. 2014 Mar;174(3):443–447.  https://doi.org/10.1001/jamainternmed.2013.13309
  33. Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management. Am J Clin Oncol. 2018 Aug;41(8):760–765.  https://doi.org/10.1097/COC.0000000000000374
  34. Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. Hepatology. 2016 Feb;63(2):590–603.  https://doi.org/10.1002/hep.28323
  35. Drug-induced liver lesions. Clinical recommendations for physicians / St. Petersburg Society of gastroenterologists, hepatologists and nutritionists. Raichelson K.L., Palgova L.K., Kondrashina E.A., Marchenko N.V., Baranovsky A.Yu. – St. Petersburg, 2017. – 116 p. 
  36. Larionova V.B., Snegovoy A.V. Correction possibilities of drug-induced liver toxicity in the treatment of patients with blood system tumors. Oncohematology. 2020;15(4):65-81. (In Russ.) https://doi.org/10.17650/1818-8346-2020-15-4-65-81
  37. Ivashkin V.T., Raikhelson K.L., Palgova L.K., Maevskaya M.V., Gerasimova O.A., Kondrashina E.A., Marchenko N.V., Baranovsky A.Yu. Drug-induced liver injury in cancer patients. Oncohematology. 2020;15(3):80-94. (In Russ.) https://doi.org/10.17650/1818-8346-2020-15-3-80-94
  38. Tkachenko P.E., Ivashkin V.T., Maevskaya M.V. Clinical recommendations for the correction of hepatotoxicity induced by antitumor therapy: practical recommendations RUSSCO. Malignant Tumors. 2019;9(3s2):595-608.  https://doi.org/10.18027/2224-5057-2019-9-3s2-595-608
  39. Practice guidelines for drug treatment of malignant tumors. Practice guidelines for supportive care in oncology. Malignant Tumors. 2015;(4s):1-456.  https://doi.org/10.18027/2224-5057-2015-4s-1-456
  40. Snegovoi A.V., Larionova V.B., Zeynalova P.A. et al. Final results of the prospective multicenter P12-717 program (use of Heptral in chronic liver disease caused by drug-induced liver damage due to chemotherapy). Bulletin of the RNTS named after N.N. Blokhin RAMS. 2016;2:143–56 (In Rus.)
  41. Perlamutrov Y, Bakulev A, Korsunskaya I, Orlov E, Bolotnikova N. Ademetionine in treatment of drug induced liver injury: an observational study in Russian patients, receiving immunosuppressive therapy for psoriasis. Int J Pharm Sci Res. 2014;5(12):5163–5169. https://doi.org/10.13040/IJPSR.0975-8232.5(12).5163-69
  42. Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol. 2012 Nov;57(5):1097–1109. https://doi.org/10.1016/j.jhep.2012.04.041
  43. Sharma A, Gerbarg P, Bottiglieri T, Massoumi L, Carpenter LL, Lavretsky H, Muskin PR, Brown RP, Mischoulon D; as Work Group of the American Psychiatric Association Council on Research. S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research. J Clin Psychiatry. 2017;78(6): e656–e667. https://doi.org/10.4088/JCP.16r11113
  44. Virukalpattigopalratnam MP, Singh T, Ravishankar AC. Heptral (ademetionine) in patients with intrahepatic cholestasis in chronic liver disease due to non-alcoholic liver disease: results of a multicentre observational study in India. J Indian Med Assoc. 2013 Dec;111(12):856–859. 
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.